Rusfertide: Molecular Structure

Molecular Structure#

Rusfertide (PTG-300) is a synthetic minihepcidins -- an engineered peptide that captures the essential ferroportin-binding domain of the native hepcidin hormone while overcoming its pharmacological limitations. Native hepcidin is a 25-amino acid peptide with four disulfide bonds that is difficult to synthesize, prone to aggregation, and has a very short half-life. Rusfertide addresses these challenges through rational peptide engineering.

Design Principles#

The development of minihepcidins followed the observation that the N-terminal region of hepcidin (approximately the first 7-9 residues) is critical for ferroportin binding and internalization. Rusfertide was designed to:

1. Retain the ferroportin-binding pharmacophore: The peptide preserves the key amino acid residues responsible for ferroportin engagement
2. Incorporate a disulfide bridge: A single disulfide bond stabilizes the bioactive conformation
3. Include a fatty acid modification: A C16 palmitoyl chain conjugated through a gamma-glutamic acid linker promotes albumin binding in circulation, extending the half-life to support once-weekly dosing
4. Improve manufacturability: Reduced complexity compared to full-length hepcidin (four disulfide bonds)

Chemical Properties#

Pharmacokinetics#

Rusfertide exhibits pharmacokinetic properties suitable for once-weekly subcutaneous administration:

• Half-life: Approximately 3-4 days, supporting weekly dosing
• Absorption: Subcutaneous injection with predictable absorption kinetics
• Distribution: Albumin binding via the fatty acid chain extends circulation time
• Metabolism: Proteolytic degradation
• Dose proportionality: Pharmacokinetic parameters scale proportionally with dose across the 10-120 mg range

Pharmacodynamics#

The pharmacodynamic effect of rusfertide is characterized by:

• Rapid reduction in serum iron and transferrin saturation following injection
• Dose-dependent restriction of iron availability for erythropoiesis
• Hematocrit reduction within the first weeks of treatment
• Reversible effects -- treatment interruption restores iron availability and hematocrit rises

Comparison with Native Hepcidin#

Stability#

Rusfertide has been formulated in both lyophilized powder and aqueous formulations for subcutaneous injection. The aqueous formulation was evaluated in a phase 1 study (Modi et al., 2024) and demonstrated acceptable stability and pharmacokinetic/pharmacodynamic profiles in healthy volunteers.

Molecular Context#

Rusfertide belongs to the Immune category of research peptides. The molecular properties of Rusfertide determine its pharmacological behavior, including receptor binding, distribution, metabolism, and elimination. Understanding these properties is fundamental to interpreting clinical data and designing research protocols.

Structural Overview#

Rusfertide is characterized as: Rusfertide is a synthetic minihepcidins peptide engineered to retain the ferroportin-binding pharmacophore of native hepcidin. It contains a disulfide bridge and a C16 fatty acid moiety conjugated via a gamma-glutamic acid linker to enhance albumin binding and extend half-life. The peptide binds ferroportin with high potency (EC50 ~5 nM)..

Amino Acid Sequence Details#

The amino acid sequence of Rusfertide is: Iva-D-T-H-F-P-C-I-K(gGlu-C16)-F-E-P-R-S-K-G-C-K-NH2 (disulfide: Cys6-Cys16). This sequence determines the peptide's three-dimensional structure, receptor binding properties, and biological activity.

Pharmacokinetic Profile#

Half-Life: ~3-4 days (supporting once-weekly dosing)

The half-life of a peptide influences dosing frequency, duration of effect, and the clinical utility of the compound. Researchers should consider the half-life when designing experimental protocols.

Related Reading#

• Rusfertide overview and research guide
• Peptides similar to Rusfertide
• Rusfertide research evidence